MTBVAC will move to Phase 2 trials in 2018
The new Spanish TB vaccine MTBVAC has received 12 million euros to carry out Phase 2a trials in new-borns and in adults in South Africa.
To read the press release, click here.
By TuBerculosis Vaccine Initiative (TBVI)
Published: Oct. 25, 2017, 3:44 p.m.
Last updated: Oct. 25, 2017, 3:47 p.m.
